Growth Metrics

Halozyme Therapeutics (HALO) Non-Current Debt (2021 - 2025)

Halozyme Therapeutics (HALO) has disclosed Non-Current Debt for 5 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 42.29% to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 42.29% increase, with the full-year FY2025 number at $2.1 billion, up 42.29% from a year prior.
  • Non-Current Debt was $2.1 billion for Q4 2025 at Halozyme Therapeutics, up from $800.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $2.1 billion in Q4 2025 to a low of $787.3 million in Q4 2021.
  • A 5-year average of $1.4 billion and a median of $1.5 billion in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 89.62% in 2022, then plummeted 46.81% in 2025.
  • Halozyme Therapeutics' Non-Current Debt stood at $787.3 million in 2021, then soared by 89.62% to $1.5 billion in 2022, then rose by 0.43% to $1.5 billion in 2023, then increased by 0.44% to $1.5 billion in 2024, then surged by 42.29% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for HALO's Non-Current Debt are $2.1 billion (Q4 2025), $800.1 million (Q3 2025), and $1.5 billion (Q1 2025).